Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648884 | 0.94 | GCGR (0.52) | GCGRMAPTLMNAMAPK1TSHR | |
| SCHEMBL2647610 | 0.89 | GCGR (0.60) | GCGRMAPTTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL2647652 | 0.88 | GCGR (0.62) | GCGRMAPTTSHRTDP1ALDH1A1 | |
| SCHEMBL2648956 | 0.88 | GCGR (0.47) | GCGRMAPTLMNATDP1L3MBTL1 | |
| SCHEMBL2649721 | 0.88 | GCGR (0.62) | GCGRMAPTTSHRTDP1ALDH1A1 | |
| SCHEMBL2648799 | 0.86 | MAPT (0.43) | GCGRMAPTLMNAMAPK1TSHR | |
| SCHEMBL2649666 | 0.85 | GCGR (0.42) | GCGRMAPTLMNAMAPK1TSHR | |
| SCHEMBL2647443 | 0.83 | GCGR (0.67) | GCGR | |
| SCHEMBL2647686 | 0.80 | GCGR (0.48) | GCGRMAPTLMNAMAPK1TSHR | |
| SCHEMBL2649457 | 0.80 | GCGR (0.43) | GCGRMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | claimed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | claimed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |